Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss
NCT06734273Phase 1Active, not recruiting
- Start
- Mar 2025
- Primary completion
- Sep 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tirzepatide in obesity (2 arms). Primary endpoint: Weight Loss at 12 months. Started Mar 2025; status: active, not recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06734273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06734273.